Corcept Therapeutics · 9 hours ago
Oncology Market Intelligence & Decision Sciences Intern
Corcept Therapeutics is a leading company in the research and development of cortisol modulators, focused on advancing treatments for serious diseases. The intern will support the Oncology Market Intelligence & Decision Sciences team by generating commercial insights and collaborating with cross-functional partners to guide decision-making across the oncology portfolio.
BiotechnologyMedicalPharmaceutical
Responsibilities
Generate and deliver actionable insights related to launch performance by analyzing early uptake dynamics, identifying barriers and drivers and providing clarity on emerging trends to guide ongoing launch activities
Contribute to a variety of cross-functional projects across the MINDS team, supporting forecasting, market research, competitive intelligence and analytics initiatives while integrating data-driven insights from primary and secondary sources to shape brand strategies
Deliver a department presentation at the end of the program
Participate as a member of the 2026 intern team group project that includes a company-wide presentation
Qualification
Required
Strong analytical skills with ability to synthesize large amounts of data and generate meaningful insights
Excellent communication, presentation and interpersonal skills with ability to distil complex insights into simple messages
Experience with Excel, PowerPoint, analytics tools, etc
This is a full-time internship (40 hours per week). Must be able to complete at least 10 consecutive weeks between June and August
Must be able to work at our Redwood City office for the duration of the internship, no relocation available
Bachelor's degree required
Applicants must be currently authorized to work in the United States on a full-time basis
Preferred
advanced degree (MBA, MS or PhD) preferred
Prior experience in the drug/biotech industry and knowledge of oncology landscape preferred
Knowledge of pharma market research, analytics and forecasting methodologies preferred
Company
Corcept Therapeutics
Corcept Therapeutics discovers and develops drugs that regulate the effects of cortisol.
Funding
Current Stage
Public CompanyTotal Funding
$119.09MKey Investors
Paperboy Ventures
2012-07-02IPO
2012-04-10Post Ipo Equity· $0.53M
2011-01-21Post Ipo Equity· $39M
Recent News
2025-12-22
thefly.com
2025-12-16
2025-12-16
Company data provided by crunchbase